Skip to main content
. 2014 Apr 8;3(4):909–918. doi: 10.1002/cam4.244

Figure 2.

Figure 2

Kaplan–Meier plot of the progression-free survival (PFS) in patients with ovarian carcinoma. Patients are grouped based on Wilms' tumor gene 1 (WT1) IgG Ab titer level. Median (18.8 WRU) is used for a cut-off level. (A) PFS for entire cohort of ovarian carcinoma patients. (B) PFS for patients with serous ovarian carcinoma. (C) PFS for patients with nonserous subtypes. (D) PFS for patients diagnosed with advanced clinical stages III or IV. (E) PFS for patients identified with grade 3.